Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab

被引：0
|
作者：
Gudesblatt, Mark [1 ,2 ]
Zarif, Myassar [2 ]
Bumstead, Barbara [2 ]
Buhse, Marijean [2 ]
Kaczmarek, Olivia [2 ]
Li, Hanyue [3 ]
Sun, Zhaonan [3 ]
Scott, Nicole [3 ]
Mendoza, Jason P. [3 ]
Avila, Robin L. [3 ]
机构：
[1] Langone South Shore Neurol Associates, 77 Medford Ave, Patchogue, NY 11772 USA
[2] NYU Langone South Shore Neurol Associates PC, Patchogue, NY USA
[3] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL | 2023年 / 9卷 / 04期
关键词：
Multiple sclerosis; natalizumab; COVID-19; vaccine;
D O I：
10.1177/20552173231218117
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The immunomodulatory effects of disease-modifying therapies for multiple sclerosis might affect the immune response to vaccines for severe acute respiratory syndrome coronavirus 2. We analyzed the severe acute respiratory syndrome coronavirus 2-specific antibody response and lymphocyte profile before and after Ad26.COV2.S (Johnson & Johnson) vaccination in natalizumab-treated patients with multiple sclerosis. There was a 72-fold increase in mean anti-severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G levels 4 weeks after vaccination and a 137-fold increase after 6 months. Other immune signals were within normal ranges. Natalizumab-treated patients with multiple sclerosis had a robust immune response to Ad26.COV2.S vaccine, and other immune signals were not significantly affected.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A case report of vaccine-induced immune thrombocytopenia and thrombosis syndrome after Ad26.COV2.S vaccine (Janssen/Johnson & Johnson)
    Castan, Maxime
    Damin-Pernik, Marlene
    Thiery, Guillaume
    Page, Dominique
    Smadja, David M.
    Bertoletti, Laurent
    THERAPIE, 2022, 77 (06): : 734 - 737
  • [32] Humoral immune response after different SARS-CoV-2 vaccination regimens
    Ruben Rose
    Franziska Neumann
    Olaf Grobe
    Thomas Lorentz
    Helmut Fickenscher
    Andi Krumbholz
    BMC Medicine, 20
  • [33] Humoral immune response after different SARS-CoV-2 vaccination regimens
    Rose, Ruben
    Neumann, Franziska
    Grobe, Olaf
    Lorentz, Thomas
    Fickenscher, Helmut
    Krumbholz, Andi
    BMC MEDICINE, 2022, 20 (01)
  • [34] Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
    Petrone, Linda
    Tortorella, Carla
    Aiello, Alessandra
    Farroni, Chiara
    Ruggieri, Serena
    Castilletti, Concetta
    Meschi, Silvia
    Cuzzi, Gilda
    Vanini, Valentina
    Palmieri, Fabrizio
    Prosperini, Luca
    Haggiag, Shalom
    Galgani, Simona
    Grifoni, Alba
    Sette, Alessandro
    Gasperini, Claudio
    Nicastri, Emanuele
    Goletti, Delia
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [35] Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
    Antonio Gallo
    Rocco Capuano
    Giovanna Donnarumma
    Alvino Bisecco
    Elena Grimaldi
    Miriana Conte
    Alessandro d’Ambrosio
    Nicola Coppola
    Massimiliano Galdiero
    Gioacchino Tedeschi
    Neurological Sciences, 2021, 42 : 3523 - 3526
  • [36] Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study
    Idda, Maria Laura
    Pitzalis, Maristella
    Lodde, Valeria
    Loizedda, Annalisa
    Frau, Jessica
    Lobina, Monia
    Zoledziewska, Magdalena
    Virdis, Francesca
    Delogu, Giuseppe
    Marini, Maria Giuseppina
    Mingoia, Maura
    Masala, Marco
    Lorefice, Lorena
    Fronza, Marzia
    Carmagnini, Daniele
    Carta, Elisa
    Pilotto, Silvy
    Castiglia, Paolo
    Chessa, Paola
    Uzzau, Sergio
    Farina, Gabriele
    Solla, Paolo
    Steri, Maristella
    Devoto, Marcella
    Fiorillo, Edoardo
    Floris, Matteo
    Zarbo, Roberto Ignazio
    Cocco, Eleonora
    Cucca, Francesco
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [37] Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
    Gallo, Antonio
    Capuano, Rocco
    Donnarumma, Giovanna
    Bisecco, Alvino
    Grimaldi, Elena
    Conte, Miriana
    d'Ambrosio, Alessandro
    Coppola, Nicola
    Galdiero, Massimiliano
    Tedeschi, Gioacchino
    NEUROLOGICAL SCIENCES, 2021, 42 (09) : 3523 - 3526
  • [38] Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies
    de la Maza, Susana Sainz
    Walo-Delgado, Paulette Esperanza
    Rodriguez-Dominguez, Mario
    Monreal, Enric
    Rodero-Romero, Alexander
    Chico-Garcia, Juan Luis
    Pariente, Roberto
    Rodriguez-Jorge, Fernando
    Ballester-Gonzalez, Ruben
    Villarrubia, Noelia
    Romero-Hernandez, Beatriz
    Masjuan, Jaime
    Costa-Frossard, Lucienne
    Villar, Luisa Maria
    VACCINES, 2023, 11 (04)
  • [39] Humoral immune response to influenza vaccine in natalizumab-treated MS patients
    Vagberg, Mattias
    Kumlin, Urban
    Svenningsson, Anders
    NEUROLOGICAL RESEARCH, 2012, 34 (07) : 730 - 733
  • [40] Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COV2.S vaccine: a case report and literature review
    Betetto, Laura Dordevic
    Luzar, Bostjan
    Tkalec, Ziva Pipan
    Ponorac, Svjetlana
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2022, 31 (02): : 83 - 87
12345